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Abstract
Background: Knowledge of existing prescription patterns in the treatment of newly-diagnosed
hypertension can provide useful information for improving clinical practice in this field. The aims of
this study are to determine the prescription patterns and time trends for antihypertensive
medication in newly-diagnosed cases of uncomplicated hypertension in Taiwan and to compare
these with current clinical guidelines.
Methods: A total of 6,536 newly-diagnosed patients with uncomplicated hypertension, aged ≥30
years, were identified from the representative 200,000-person sample in the computerized
reimbursement database of the National Health Insurance in Taiwan. These patients were followed
from 1998 to 2004 with all diagnoses, prescription data and medication charges being retrieved for
subsequent analysis.
Results: Prescription patterns varied by age, gender and clinical facilities, with mono-therapies
being found to be dominant in the first year, albeit declining over time. Calcium channel blockers
and beta-blockers were the most frequently prescribed antihypertensive drugs, either alone or in
combinations. Although least expensive, the prescription rates of diuretics were low, at 8.3% for
mono-therapies and 19.9% overall. The prescription rate for angiotensin receptor blockers (ARBs)
was elevated considerably over time. After controlling for other related factors by multiple logistic
regression analysis, ARBs were found to be prescribed mainly by medical centers or regional
hospitals.
Conclusion: These findings indicate the existence of a gap between current clinical practice and
the desired goal of cost-effectiveness in antihypertensive treatment in Taiwan, which should be
corrected.
Background
Hypertension, a leading contributor to the global burden
of causes of disease, continues its upward growth trend [1-
4]. Poor control of this highly prevalent disease can lead
to the development of ischemic heart disease, heart fail-
ure, stroke and chronic renal insufficiency [3-7]. Along
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with its comorbidities, hypertensive related conditions
have accounted for almost a third of the total causes of
death in Taiwan in recent years [8]; in 2003 the total phar-
maceutical expenditure on antihypertensive medication
was US$0.32 billion, accounting for approximately 27%
of the overall annual outpatient pharmaceutical expendi-
ture on western-style medicines [9].
As a result of various clinical trials and studies, a range of
clinical guidelines on antihypertensive treatment have
been published over the past decade [10-15]. Based on
clinical evidence and cost-effectiveness [16-18], guide-
lines developed by the Joint National Committee (JNC)
in the United States [11] and the National Institute for
Health and Clinical Excellence (NICE) in the United King-
dom [13] recommended that diuretics (particularly thi-
azide-type diuretics) should be the drug of first choice for
patients with no compelling indications. However, the
results of various studies have shown that adherence to
such clinical guidelines and recommendations are not at
all uniform; indeed, they have been found to vary by time
period and country, and by the characteristics of patients
and physicians [19-23].
Taiwan's National Health Insurance (NHI) has not yet
established a definite guideline for antihypertensive drug
therapy. Given the enormous growth in healthcare
expenditure within the NHI (from US$13.9 billion in
1997 to US$20.5 billion in 2005) [24] and the limited
resources for healthcare, there is a clear need to explore
physician practices, including prescription trends, in anti-
hypertensive and other therapies [25,26].
The computerized reimbursement database of the NHI in
Taiwan provides us with a valuable opportunity to assess
the real practice patterns of antihypertensive pharmaceu-
tical therapies. The NHI program, which is a mandatory
nationwide health insurance system, was implemented in
Taiwan in March 1995. Overall coverage continues to rise,
from 96.2% in 2000 to 98.3% in 2006, and almost the
entire population of Taiwan is now covered by the system
[27]. Furthermore, in contrast to the NHI systems of many
Western nations, patients in Taiwan are free to choose care
providers in a competitive healthcare market.
The objectives of this study are to determine antihyperten-
sive medication prescription patterns and time trends
among newly-diagnosed cases of uncomplicated hyper-
tension in Taiwan, to attempt to identify the determinants
of the choice of first-line drug therapy, and to investigate
the pharmaceutical costs associated with different antihy-
pertensive agents.
Methods
Study population
This study uses a 200,000-person representative random
sample from the computerized reimbursement database
of the NHI, between January 1997 and December 2004.
Details on the gender and date of birth of the patients, the
date of prescription, commercial names of drugs, drug
dosages/duration and costs for each prescription are
recorded in the reimbursement files.
Patients initially identified were newly-diagnosed with
essential hypertension on at least three occasions, were
being treated for this condition, and had received their
first antihypertensive medication between 1 January 1998
and 31 December 2004. In order to verify that a case was
a new one, a period of at least one year was required (Jan-
uary to December of 1997) without any treatment and/or
diagnosis relating to hypertension.
To prevent potential confounding by comorbidities in the
prescription patterns of antihypertensive agents at differ-
ent clinical facilities, patients diagnosed with suspected
diabetes mellitus, ischemic heart disease, diseases of pul-
monary circulation, other forms of heart diseases (includ-
ing dysrhythmia and heart failure), stroke or renal
diseases were excluded from the sample. In order to
ensure adherence to these criteria, any of the above diag-
noses may not have appeared in any hospitalization file
prior to the patient having been diagnosed as hyperten-
sive, and the diagnoses may not have appeared more than
three times in ambulatory outpatient files. We discarded
those diagnoses appeared only once or twice in ambula-
tory outpatient files to exclude suspected or uncertain
cases where claims were filed to allow for further diagnos-
tic examination.
Prescription patterns of new cases of hypertension
All antihypertensive drug prescription records from
ambulatory care claims and prescriptions dispensed at
contracted pharmacies were retrieved and analyzed for
our sample of newly-diagnosed patients aged ≥30 years.
Patients were stratified by gender and age, with age being
split into two sub-groups: the younger group (30–54 years
of age) and the older group (≥55 years). The clinical facil-
ities were classified into four types, medical centers,
regional hospitals, local hospitals and primary care clin-
ics, based upon the level of medical care provided and the
size of the institution as recognized by the NHI.
Antihypertensive drugs were categorized according to the
1999 World Health Organization-International Society
Hypertension Guidelines for the Management of Hyper-
tension (WHO/ISH, 1999) and the Seventh Report of the
Joint National Committee on Prevention, Detection, Eval-
uation and Treatment of High Blood Pressure (JNC 7)BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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[10,11]. Six major categories of antihypertensive drugs
generally are available, including angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers
(ARBs), beta-blockers, calcium channel blockers (CCBs),
diuretics, and others (all other antihypertensive classes
including alpha-blockers).
Prescriptions for a chronic disease in Taiwan, such as
hypertension, most frequently involved the prescribing of
drugs for 28- to 90-day periods, which would allow the
patient visit a doctor every one to three months. Since
each prescription may have contained different combina-
tions of drugs and durations of medication, analysis of the
data was undertaken using the prescription rate as calcu-
lated as the number of prescriptions containing a specific
antihypertensive agent divided by the total number of pre-
scriptions. A comparison of the prescription time trend
was undertaken for each year, beginning with the first
antihypertensive prescription. Daily drug costs, excluding
all pharmacy service fees or other peripheral costs, were
also calculated for each prescription. The drug costs are set
by the Bureau of NHI and universally applied to clinical
facilities regardless of their sizes.
Statistical analysis
After being weighted by duration of medication, daily
drug costs are expressed as time-weighted means, while
other results are expressed as means ± standard deviation
(SD). The Chi-square test was carried out to determine the
statistical significance of the differences between the pre-
scription rates, with the Cochran-Armitage test also per-
formed to assess the linear time trends over the sample
period from the time of the initial treatment. Means of
daily drug costs were compared using the Student t-test.
Finally, multiple logistic regression analysis was per-
formed to identify possible influential factors as a result of
the prescribing of a single class of antihypertensive medi-
cation as a mono-therapy. SAS version 9.1 for Windows
was used for the analysis of all of the data in this study. All
tests were two-sided, and a p-value of <0.05 was consid-
ered statistically significant. Whenever multiple compari-
sons were performed, Bonferroni adjustments were made
accordingly.
Results
The dataset contained a total of 15,835 patients over the
age of 30 years who had received their initial dose of anti-
hypertensive drugs for essential hypertension between 1
January 1998 and 31 December 2004. Of this total, 9,299
were excluded on the basis that one or more earlier
comorbidities had been recorded. We were therefore left
with a total of 6,536 patients and 178,754 prescriptions
for antihypertensive agents for subsequent analysis.
Of the total sample of 6,536 patients, 3,268 (50.0%) were
women and 49.3% were ≥55 years old, with a mean of
55.9 and SD of 12.3 years. The mean follow-up duration
after the first prescription of antihypertensive medication
was 42.8 ± 27.2 months, while the average number of
overall prescriptions was 27.3 ± 26.0. Each prescription
included 1.64 ± 0.84 antihypertensive drugs prescribed
for an average period of 22.3 ± 10.5 days. The mean
number of actual medical visits over the entire period of
study was 25.1 ± 24.5.
Antihypertensive prescriptions among newly-diagnosed 
patients
Over half of the prescriptions for newly-diagnosed cases
of uncomplicated hypertension involved single antihy-
pertensive drug therapy (n = 94,797; 53.0%), with women
and older patients receiving more mono-therapies. Medi-
cal centers and regional hospitals prescribed more combi-
nation therapies, as compared with primary care clinics
(Table 1). The percentage of mono-therapy treatments
declined over time from the initial diagnosis, whereas
there was a gradual increase in the percentage of combina-
tion therapies (Figure 1). The 10 most frequently pre-
scribed antihypertensive regimens, ranked in order of
prescribing frequency, were as follows: CCBs (17.7%),
beta-blockers (14.5%), ACEIs (8.2%), CCBs + beta-block-
ers (7.7%), others (5.3%), diuretics (4.4%), CCBs + ACEIs
(4.0%), ARBs (3.0%), CCBs + ARBs (2.6%), beta-blockers
+ diuretics (2.4%).
A summary of the total number of prescriptions for the
different categories of antihypertensive drugs is provided
in Table 2, where it is shown that the most frequently pre-
scribed antihypertensive agents were CCBs (n = 92,574;
51.8%), with beta-blockers as the second most frequently
prescribed, followed by ACE inhibitors, diuretics, others
and ARBs.
The prescription rate for ARBs, which was the highest in
medical centers (22.6%), was almost five times the rate for
primary care clinics, and was also higher than the prescrip-
tion rate for ACE inhibitors and diuretics. There was an
increase with time in the number of prescriptions for
ARBs, CCBs and diuretics, whereas the number of pre-
scriptions for ACE inhibitors remained stable (Figure 2).
Mono-therapies for new cases of uncomplicated 
hypertension
Among all of the mono-therapy prescriptions, the most
frequently prescribed antihypertensive agents were CCBs
(n = 31,711; 33.5%) and beta-blockers (n = 25,835;
27.3%). Older patients (aged over 55 years) were treated
with CCBs more often than younger patients, with beta-
blockers being more frequently prescribed among the lat-
ter group.BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
Page 4 of 11
(page number not for citation purposes)
The prescription rates for beta-blockers were higher
among women and younger patients (p < 0.0001), while
the prescription rates for diuretics were higher among
women and older patients (p < 0.0001). In contrast, ACE
inhibitors and ARBs were more frequently prescribed for
younger patients. Medical centers and regional hospitals
were found to have prescribed ARBs much more often
than primary care clinics (p < 0.0001), where the prescrib-
ing of ACE inhibitors was found to be much more com-
mon (p < 0.0001) (Table 3).
With the passage of time from the date of the initial ther-
apy, there was a significant increase in the prescription
rate for ARBs, from 3.8% in the first year to 10.3% in the
seventh year (p < 0.0001). There was also an increase over
time in mono-therapies comprising diuretics; however,
there was a reduction over time in the trends for mono-
therapies involving beta-blockers or ACE inhibitors (p <
0.0001). The time trends for mono-therapies are summa-
rized in Figure 3.
Daily drug costs for different antihypertensive mono-
therapies
The daily costs for mono-therapy medication, in order
from low to high, are as follows. Diuretics were the cheap-
est with a mean of US$0.17, followed by beta-blockers
(US$0.27) and others (US$0.28). The costs for CCBs and
ACE inhibitors were almost the same (US$0.56), while
the costs for ARBs, at a daily average of US$0.85, were
about five times those of diuretics. With the exception of
the class of 'other' drugs, the means of the daily drug costs
did not vary significantly by gender, age or clinical facility.
Factors associated with initial ARB mono-therapy 
prescriptions
As Table 4 shows, following adjustment by multiple logis-
tic regression analysis, those prescriptions involving ARBs
as an antihypertensive mono-therapy were found to be
associated with subsequent diagnoses of diabetes mellitus
(odds ratio (OR) = 1.5; 95% CI: 1.4–1.7), regional hospi-
tals (OR = 3.6, 95% CI: 3.3–3.9), medical centers (OR =
5.8, 95% CI: 5.3–6.2), and the period after the year 2001
(OR = 2.4 for 2001–2, and 4.5 for 2003–2004).
Discussion
This is one of the first studies of its kind to undertake an
assessment of the national prescription patterns and time
trends in Taiwan for antihypertensive medication for
uncomplicated hypertension. We found that whether in
mono-therapies or overall treatment, CCBs were the most
Prescription pattern time trends for combinations of mono-, two-, three- and four(+)-drug treatment therapies Figure 1
Prescription pattern time trends for combinations of mono-, two-, three- and four(+)-drug treatment thera-
pies. Note: * indicates p-value <0.0125 under the Cochran-Armitage trend test, being significant with Bonferroni adjustment 
for multiple comparisons (p < 0.05/4 = 0.0125).BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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commonly prescribed drugs, followed by beta-blockers.
Amongst all of the mono-therapies, the lowest average
daily medication costs were for diuretics, at less than one
third of the costs for CCBs or ACE inhibitors, and about
one fifth of the costs for ARBs. The prescription rate for
diuretics was, however, surprisingly low, accounting for
only 8.3% of all mono-therapies, and indeed the diuretic
prescription rate was the second lowest of all, only after
ARBs (5.7%).
Beginning in 2006–7, the National Health Research Insti-
tutes of Taiwan has begun to draft clinical guidelines for
various health conditions, including the treatment of
hypertension. However, most physicians seemed to accept
the recommendation of the US JNC or the WHO/ISH
guideline during the time of this study. The evidence-
based clinical guidelines for antihypertensive treatment
published by both the JNC in 2003 [11] and the NICE in
2004 [13] contained recommendations for low dosages of
thiazide diuretics as the first-line drug for essential hyper-
tension with no compelling indications. Such a recom-
mendation also appeared in the 2003 statement
published by the WHO/ISH [28]; and indeed, diuretics
have been found to be the mainly prescribed class of anti-
hypertensive drugs in the United Kingdom, Denmark and
the United States [20,29,30].
Researchers have indicated a substantial potential for cost
savings if thiazides are prescribed rather than other more
expensive drugs for treatment of hypertension [31,32].
Given that the prescription pattern in Taiwan appears to
utilize more non-thiazide medications that are generally
more expensive, this issue would be worthy of further
study with the aim of comparing the cost-effectiveness of
antihypertensive treatment in Taiwan with those of other
countries.
Considerable variation in antihypertensive prescribing
patterns exists internationally. Fretheim and colleagues
compared the sale figures of antihypertensive drugs for six
countries, reporting that thiazide diuretics accounted for
25% of consumption in the UK, while the corresponding
figure for Norway was only 6% [30]. According to our
assessment, thiazide diuretics accounted for 7.2% of over-
all antihypertensive drugs prescribed for uncomplicated
hypertension in Taiwan. The relatively low prescription
rate of thiazides for antihypertensive treatment appears
Table 1: Prescription patterns of antihypertensive therapies for newly-diagnosed uncomplicated hypertension patients, 1998–2004a
Treatment regimen
Variables Mono-therapyb Two-drug combinationsb Three-drug combinationsb Four(+)-drug combinationsb Total No. of 
prescriptionsc
No. % No. % No. % No. %
Patient gender
Male 44 738 51.36# 31 494 36.16# 6 815 7.82# 4 058 4.66# 87 105
Female 50 059 54.62 31 927 34.84 6 024 6.57 3 639 3.97 91 649
Patient age (years)
<55 40 357 50.67# 29 784 37.39# 6 130 7.70# 3 380 4.24 79 651
≥55 54 440 54.93 33 637 33.94 6 709 6.77 4 317 4.36 99 103
Type of clinical 
facilityd
Medical center 16 721 48.76# 12 693 37.02 3 897 11.37# 978 2.85# 34 289
Regional hospital 14 809 49.75# 10 453 35.11# 3 687 12.39# 819 2.75# 29 768
Local hospital 18 258 59.03# 9 745 31.51# 2 395 7.74# 531 1.72# 30 929
Primary care clinic 44 997 53.73 30 520 36.44 2 860 3.42 5 369 6.41 83 746
Total Nos. 94 797 53.03 63 421 35.48 12 839 7.18 7 697 4.31 178 754
Notes:
a Total sample number = 6 536 patients.
b No. refers to the number of prescriptions under each treatment regimen; % refers to the percentage of the total drugs prescribed under the four 
treatment regimens.
c As a result of missing data, the sum of the total number of prescriptions over the four types of clinical facilities is smaller than the overall number 
of prescriptions.
d Pairwise group comparisons are performed taking primary care clinics as the reference.
# Significant p-value with the Bonferroni-adjusted α-level, p < 0.0025B
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Table 2: Distribution of antihypertensive drugs for newly-diagnosed uncomplicated hypertension patients, by gender, age and clinical facility, 1998–2004a
Class of drugb Total No. of prescriptionsb
Variables Diuretics Beta-blockers CCBsc ACE inhibitorsc ARBsc Others
N o .%N o .%N o .%N o .%N o .%N o .%
Patient gender
Male 15 525 17.82# 34 703 39.84# 46 468 53.35# 22 825 26.20# 10 635 12.21# 15 212 17.46# 87 105
Female 19 981 21.80 40 941 44.67 46 106 50.31 21 306 23.25 10 339 11.28 8 826 9.63 91 649
Patient age (years)
<55 13 556 17.02# 39 445 49.52# 40 270 50.56# 21 282 26.72# 10 421 13.08# 7 578 9.5# 79 651
≥55 21 950 22.15 36 199 36.53 52 304 52.78 22 849 23.06 10 553 10.65 16 460 16.61 99 103
Type of clinical facilityd
Medical center 7 729 22.54# 14 463 42.18# 18 675 54.46# 6 169 17.99# 7 764 22.64# 3 122 9.10# 34 289
Regional hospital 6 025 20.24 12 320 41.39# 17 058 57.30# 6 170 20.73# 5 637 18.94# 2 958 9.94# 29 768
Local hospital 5 005 16.18# 11 303 36.54# 17 849 57.71# 5 464 17.67# 3 594 11.62# 3 905 12.63# 30 929
Primary care clinic 16 745 19.99 37 540 44.83 38 988 46.56 26 322 31.43 3 966 4.74 14 053 16.78 83 746
Total Nos. 35 506 19.86 75 644 42.32 92 574 51.79 44 131 24.69 20 974 11.73 24 038 13.45 178 754
Notes:
a Total sample number = 6 536 patients.
b No. refers to the number of prescriptions for each class of drug; % refers to the percentage of the total prescriptions for the six classes of drugs. As a result of missing data, the sum of the total number 
of prescriptions over the four types of clinical facilities is smaller than the overall number of prescriptions. The sum of the prescription rates for all six classes of drugs exceeds 100% because the average 
prescription contained more than one drug.
c CCBs = calcium channel blockers; ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers.
d Pairwise group comparisons are performed taking primary care clinics as the reference.
# Significant p-value with the Bonferroni-adjusted α-level, p < 0.0017BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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similar to those of Norway and France, and is very differ-
ent from that of the UK or Denmark.
In the absence of any guideline or effective regulations on
prescribing behavior for clinicians, the current prescrip-
tion pattern in Taiwan is probably a reflection of the
mixed effect of the preferences of physicians, the hypoten-
sive efficacies of medications, and the tolerance levels of
patients. Under a healthcare system of mixed conven-
tional medicine and traditional Chinese medicine, Tai-
wanese patients appear to dislike diuretics for the
treatment of hypertension possibly because of the label
'diuresis', a term generally regarded as treating 'edema'
and affecting one's kidney function in traditional Chinese
medicine. The mono-therapy prescription rate for diuret-
ics, at less than 10%, albeit with a slightly increasing trend
with the passage of time (as shown in Figures 2 and 3),
also implies that diuretics are currently considered in Tai-
wan to be only a second- or third-line medication; thus,
there would appear to be considerable room for improve-
ment, in terms of greater adherence to the existent clinical
guidelines based on evidence as well as cost-effectiveness
[16,18].
The trend toward increasing numbers of prescriptions
involving ARBs, as summarized in Table 4, is also worthy
of some attention. Indeed, the multiple logistic regression
analysis indicated that the calendar year and the size of
the clinical facility were actually the major determinants,
although we deliberately restricted our subjects to those
newly-diagnosed with uncomplicated hypertension and
mono-therapies to prevent systematic differences in
patients' characteristics. We have also found that primary
care clinics prescribed diuretics more frequently than the
larger medical facilities. We suspect that differences in cost
consciousness may be an important contributor to this
particular phenomenon, since the current reimbursement
policy within the NHI program seems less restrictive on
medical centers and regional hospitals, as compared with
primary local clinics. Another possibility is that physicians
in large medical facility are more frequently exposed to
new drugs and tending to readily accept the latest, or most
up-to-date, medications [33]. In fact, the number of ARBs
on the market increased from 2 to 9 during the period of
1998–2004. Some studies suggest that promotional activ-
ities of pharmaceutical industry have a major impact on
physicians' prescribing patterns [34,35]. More evidence
needs to be collected to corroborate these beliefs.
Prescription distribution time trends for antihypertensive agents Figure 2
Prescription distribution time trends for antihypertensive agents. Note: * indicates p-value <0.0083 under the 
Cochran-Armitage trend test, being significant with Bonferroni adjustment for multiple comparisons (p < 0.05/6 = 0.0083).B
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Table 3: Distribution of mono-therapy antihypertensive drug prescriptions for newly-diagnosed uncomplicated hypertension patientsa
Class of drugb Total No. of prescriptionsb
Variables Diuretics Beta-blockers CCBsc ACE inhibitorsc ARBsc Others
No. % No. % No. % No. % No. % No. %
Patient gender
Male 2 974 6.65# 11 602 25.93# 14 881 33.26 7 004 15.66 2 561 5.72 5 716 12.78# 44 738
Female 4 849 9.69 14 233 28.43 16 830 33.62 7 619 15.22 2 822 5.64 3 706 7.40 50 059
Patient age (years)
<55 2 366 5.86# 13 627 33.77# 12 083 29.94# 7 134 17.68# 2 677 6.63# 2 470 6.12# 40 357
≥55 5 457 10.02 12 208 22.42 19 628 36.05 7 489 13.76 2 706 4.97 6 952 12.77 54 440
Type of clinical facilityd
Medical center 1 067 6.38# 4 474 26.76# 5 841 34.93# 2 255 13.49# 2 099 12.55# 985 5.89# 16 721
Regional hospital 1 026 6.93# 4 144 27.98 5 690 38.42# 1 710 11.55# 1 272 8.59# 967 6.53# 14 809
Local hospital 1 363 7.47# 4 171 22.84# 8 186 44.84# 1 728 9.46# 920 5.04# 1 890 10.35# 18 258
Primary care clinic 4 367 9.71 13 043 28.99 11 991 26.65 8 927 19.84 1 089 2.42 5 580 12.40 44 997
Total Nos. 7 823 8.25 25 835 27.25 31 711 33.45 14 623 15.43 5 383 5.68 9 422 9.94 94 797
Notes:
a Total sample number of prescriptions = 94 797.
b No. refers to the number of prescriptions for each class of drug; % refers to the percentage of the total prescriptions for the six classes of drugs. As a result of missing data, the sum of the total 
number of prescriptions over the four types of clinical facilities is smaller than the overall number of prescriptions.
c CCBs = calcium channel blockers; ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers.
d Pairwise group comparisons are performed taking primary care clinics as the reference.
# Significant p-value with the Bonferroni-adjusted α-level, p < 0.0017BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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One of the limitations of this study is the potential con-
founding by severity of disease for different levels of clin-
ical facilities. Because the NHI reimbursement database
has no link to details on patients' blood pressure levels or
laboratory data, we were unable to directly compare the
severity of hypertension among various groups of
patients. Nonetheless, we have limited our study subjects
to newly diagnosed cases of uncomplicated hypertension
with mono-therapies, and for them there is no restriction
on selection of doctors under the NHI in Taiwan. In such
a way, hypertensive patients initially treated at different
clinical facilities might not be so much different in sever-
ity. Moreover, Table 4 indicated that medical centers used
more ARBs and less ACE inhibitors after adjustment for
other determinants. As the efficacy of these two types of
antihypertensive medication is similar [15], it seems that
ARBs might be prescribed to substitute for some ACE
inhibitors in medical centers or regional hospitals and
this trend probably was unrelated to the different severity
of hypertension.
The NHI database provides a 200,000-person sample rep-
resenting almost 1% of the overall population of 22.9 mil-
lion people in Taiwan; thus, we estimate that there may
have been up to 0.75 million newly-diagnosed cases of
uncomplicated hypertension in Taiwan during the seven-
year period of this study. If the daily drug costs for uncom-
plicated hypertension could be reduced by an average of
US$0.3–0.6, this would result in annual savings of up to
US$82–163 million in overall pharmaceutical expendi-
ture within Taiwan's NHI. If such action were extended to
incorporate all prevalent cases of hypertension through-
out Taiwan, the total amount of annual savings on costs
for antihypertensive drugs could even run to US$0.2 bil-
lion. Under the current limited resources, this could
clearly make the NHI much more sustainable [26].
Conclusion
The initial prescription patterns for antihypertensive ther-
apies for uncomplicated hypertension in Taiwan seem to
be inconsistent with the current international clinical
guidelines. Although diuretics are the least expensive class
of antihypertensive drugs, they are nevertheless being
used as a second- or third-line method of medication,
with a notably low prescription rate. There has been a
growing trend in the prescribing of ARBs as the initial
choice of therapy for uncomplicated hypertension, partic-
ularly in medical centers and regional hospitals. These
Time trends for single-drug antihypertensive treatment Figure 3
Time trends for single-drug antihypertensive treatment. Note: * indicates p-value <0.0083 under the Cochran-Armit-
age trend test, being significant with Bonferroni adjustment for multiple comparisons (p < 0.05/6 = 0.0083).BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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results indicate a need for greater awareness of the evi-
dence-based guidelines for antihypertensive drug therapy
amongst physicians and the general public.
Given the existence of the national health insurance sys-
tem in Taiwan, there is still significant room for improve-
ment in the cost-effectiveness of antihypertensive
treatment [16,25]. We recommend reaching a consensus
on this matter and developing a domestic clinical guide-
line taking cost-effectiveness into consideration as soon as
possible.
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Table 4: Multiple logistic regression estimates of ARB and ACE inhibitor mono-therapy prescription characteristics for newly-
diagnosed uncomplicated hypertension patients, 1998–2004*
Variables ARBs ACE inhibitors
OR 95% CI OR 95% CI
Patient gender
Female (reference) 1.00 - 1.00 -
Male 0.99 0.94–1.05 1.07 1.03–1.11
Patient age (years)
30–54 (reference) 1.00 - 1.00 -
≥55 0.74 0.70–0.78 0.75 0.72–0.78
Geographical region
Northwest (reference) 1.00 - 1.00 -
Midwest 0.74 0.68–0.80 0.98 0.93–1.02
Southwest 0.67 0.62–0.72 0.86 0.82–0.90
Eastern 1.34 1.19–1.52 1.39 1.29–1.49
Offshore islands 2.78 2.21–3.49 0.45 0.35–0.57
Type of clinical facility
Primary care clinics (reference) 1.00 - 1.00 -
Local hospitals 2.17 1.98–2.38 0.43 0.41–0.45
Regional hospitals 3.55 3.26–3.87 0.52 0.49–0.55
Medical centers 5.77 5.32–6.25 0.63 0.60–0.66
Time elapsed since initial therapy
1 year or less (reference) 1.00 - 1.00 -
2–3 years 1.00 0.92–1.09 0.93 0.89–0.97
4–7 years 1.12 1.03–1.21 0.95 0.90–1.00
Comorbidity after hypertension†
Diabetes mellitus 1.55 1.42–1.68 1.36 1.28–1.44
Ischemic heart disease 1.10 1.02–1.19 0.78 0.73–0.82
Stroke 1.02 0.93–1.11 0.98 0.91–1.05
Chronic renal disease 1.07 0.94–1.22 0.92 0.83–1.02
Calendar years
1998–2000 (reference) 1.00 - 1.00 -
2001–2002 2.35 2.12–2.62 0.87 0.83–0.91
2003–2004 4.45 4.01–4.94 0.79 0.75–0.83
Notes:
* The odds ratio (OR) for each variable was adjusted for all other variables listed in the table.
† The reference group is subjects with no corresponding comorbidity for each category after hypertension.BMC Health Services Research 2008, 8:133 http://www.biomedcentral.com/1472-6963/8/133
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